These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 33032771

  • 21. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A.
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [Abstract] [Full Text] [Related]

  • 22. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.
    Arthritis Res Ther; 2018 Jun 19; 20(1):129. PubMed ID: 29921318
    [Abstract] [Full Text] [Related]

  • 23. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
    Husni ME, Mease PJ, Merola JF, Tillett W, Goldammer N, Ink B, Coarse J, Lambert J, Taieb V, Gladman DD.
    RMD Open; 2024 Sep 23; 10(3):. PubMed ID: 39313302
    [Abstract] [Full Text] [Related]

  • 24. Golimumab for the treatment of psoriatic arthritis.
    Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.
    Health Technol Assess; 2011 May 23; 15 Suppl 1():87-95. PubMed ID: 21609657
    [Abstract] [Full Text] [Related]

  • 25. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
    Rahman P, McInnes IB, Deodhar A, Schett G, Mease PJ, Shawi M, Cua DJ, Sherlock JP, Kollmeier AP, Xu XL, Sheng S, Ritchlin CT, McGonagle D.
    Clin Rheumatol; 2024 May 23; 43(5):1591-1604. PubMed ID: 38472528
    [Abstract] [Full Text] [Related]

  • 26. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
    Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gómez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A.
    Arthritis Rheum; 2012 Aug 23; 64(8):2504-17. PubMed ID: 22378566
    [Abstract] [Full Text] [Related]

  • 27. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
    Kristensen LE, Soliman AM, Papp K, White D, Barcomb L, Lu W, Eldred A, Behrens F.
    Rheumatology (Oxford); 2023 Feb 01; 62(2):629-637. PubMed ID: 35801915
    [Abstract] [Full Text] [Related]

  • 28. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK, FUTURE 2 Study Group.
    Arthritis Res Ther; 2018 Jun 07; 20(1):113. PubMed ID: 29880010
    [Abstract] [Full Text] [Related]

  • 29. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.
    Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S.
    Arthritis Care Res (Hoboken); 2016 Feb 07; 68(2):267-74. PubMed ID: 25779603
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study.
    Mease P, Elaine Husni M, Chakravarty SD, Kafka S, Parenti D, Kim L, Hung Lo K, Hsia EC, Kavanaugh A.
    ACR Open Rheumatol; 2020 Nov 07; 2(11):640-647. PubMed ID: 33073933
    [Abstract] [Full Text] [Related]

  • 31. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V, Mease PJ, Soriano ER, Kishimoto M, Salvarani C, Saffore CD, Zueger P, McDearmon-Blondell E, Kato K, Gladman DD.
    Rheumatol Ther; 2021 Dec 07; 8(4):1789-1808. PubMed ID: 34636026
    [Abstract] [Full Text] [Related]

  • 32. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Deodhar A, Shiff NJ, Gong C, Chan EKH, Hsia EC, Lo KH, Akawung A, Kim L, Xu S, Reveille JD.
    Rheumatol Ther; 2023 Aug 07; 10(4):983-999. PubMed ID: 37322274
    [Abstract] [Full Text] [Related]

  • 33. Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
    Blauvelt A, Leonardi CL, Gaylis N, Jauch-Lembach J, Balfour A, Lemke L, Hachaichi S, Brueckmann I, Festini T, Wiland P.
    BioDrugs; 2021 Mar 07; 35(2):229-238. PubMed ID: 33651341
    [Abstract] [Full Text] [Related]

  • 34. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.
    J Rheumatol; 2008 Jan 07; 35(1):20-30. PubMed ID: 18050385
    [Abstract] [Full Text] [Related]

  • 35. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
    Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF.
    J Rheumatol; 2010 Jun 07; 37(6):1221-7. PubMed ID: 20395648
    [Abstract] [Full Text] [Related]

  • 36. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song IH, Enejosa J, Schlacher C, Song Y, Fleischmann R.
    Rheumatology (Oxford); 2021 Dec 01; 60(12):5583-5594. PubMed ID: 33590829
    [Abstract] [Full Text] [Related]

  • 37. Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.
    Strand V, Gossec L, Coates LC, Ogdie A, Choi J, Becker B, Zhuo J, Lehman T, Nowak M, Elegbe A, Mease PJ, Deodhar A.
    Arthritis Care Res (Hoboken); 2024 Aug 01; 76(8):1139-1148. PubMed ID: 38529674
    [Abstract] [Full Text] [Related]

  • 38. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, Pimenta S, Pimentel-Santos FM, Gomes JL, Aguiar R, Pinto P, Videira T, Catita C, Santos H, Borges J, Sequeira G, Ribeiro C, Teixeira L, Ávila-Ribeiro P, Martins FM, Canhão H, McInnes IB, Ribeiro RM, Fonseca JE.
    Ann Rheum Dis; 2020 Apr 01; 79(4):490-498. PubMed ID: 32193187
    [Abstract] [Full Text] [Related]

  • 39. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators.
    Arthritis Care Res (Hoboken); 2015 Dec 01; 67(12):1627-36. PubMed ID: 25623393
    [Abstract] [Full Text] [Related]

  • 40. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
    Orbai AM, Ogdie A, Gossec L, Tillett W, Leung YY, Gao J, Trivedi M, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Coates LC.
    Rheumatology (Oxford); 2020 Jul 01; 59(7):1495-1504. PubMed ID: 31624837
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.